China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Short Percentage of Float


SHSE:600062 China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
90 GF Score
Price ¥16.43
GF Value ¥18.75
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is China Resources Double-Crane Pharmaceutical Co Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SHSE:600062 vs ZTS, UTHR: Short Percentage of Float Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Resources Double-Crane Pharmaceutical Co Short Percentage of Float vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Double-Crane Pharmaceutical Co's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where China Resources Double-Crane Pharmaceutical Co's Short Percentage of Float falls into.


SHSE:600062
90GF Score
China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥16.43 is trading 12.4% below its estimated GF Value™ of ¥18.75. GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600062:

  • Short Percentage of Float:
  • GF Value™: ¥18.75 vs. price of ¥16.43 (12.4% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Resources Double-Crane Pharmaceutical Co Business Description

Address No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score

Get the complete analysis for SHSE:600062

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.43
Price
¥18.75
GF Value